{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:06:20Z","timestamp":1789736780531,"version":"4.0.1"},"reference-count":42,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T00:00:00Z","timestamp":1501113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:p>Driving under the influence of drugs (DUID) is a worldwide problem. Several countries have adopted DUID legislations which prove their deterrent effect and impact on road safety. However, the use of new psychoactive substances (NPS) and prescription drugs is not known, as the applied roadside screening tests have not yet been adapted for these compounds. In this study, 558 blood samples obtained during roadside controls in Belgium (January to August 2015) after a positive Drugwipe 5S\u00ae test and 199 oral fluid (OF) samples obtained from negatively screened test pads were analyzed. The NPS positivity rate was 7% in blood, while it reached 11% in OF. NPS detected were: diphenidine, ketamine, 4\u2010fluoroamphetamine, 2\u2010amino\u2010indane, methoxetamine, \u03b1\u2010PVP, methiopropamine, a mix of 5\u2010MAPB\/5\u2010EAPB, TH\u2010PVP, mephedrone, methedrone, 4\u2010methylethylcathinone, 5\u2010MeO\u2010DALT, 4\u2010Acetoxy\u2010DiPT, AB Fubinaca, FUB\u2010JWH018, JWH020, trifluoromethylphenylpiperazine, and ethylphenidate. Moreover, 17% of blood samples (and 5% of OF) contained an analgesic drug, 10% (0.5%) a benzodiazepine\/hypnotic, 5% (2%) an antidepressant, 2% (3%) an antipsychotic, 2% an antiepileptic drug, and 1% methylphenidate. The presence of NPS in the young (and predominately male) DUID population is proven. Furthermore, a high level of poly\u2010drug use including combinations of NPS, licit, and drugs of abuse was observed. Further research concerning the development of on\u2010site NPS detection techniques should be established. Meanwhile, the effects of combined drug use on driving ability and the physical\/psychological signs after NPS use should be performed to improve the on\u2010site DUID detection of NPS by police officers, so they can engage in blood sampling for a general unknown screening.<\/jats:p>","DOI":"10.1002\/dta.2232","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T14:42:52Z","timestamp":1498142572000},"page":"539-547","source":"Crossref","is-referenced-by-count":63,"title":["Prevalence of new psychoactive substances and prescription drugs in the Belgian driving under the influence of drugs population"],"prefix":"10.1002","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2683-9379","authenticated-orcid":false,"given":"S. M. R.","family":"Wille","sequence":"first","affiliation":[{"name":"Laboratory of Toxicology National Institute of Criminalistics and Criminology  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Richeval","sequence":"additional","affiliation":[{"name":"CHU Lille, Unit\u00e9 Fonctionnelle de Toxicologie  Lille France"},{"name":"University Lille, EA 4483 \u2013 IMPECS \u2013 IMPact de l'Environnement Chimique sur la Sant\u00e9 humaine  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nachon\u2010Phanithavong","sequence":"additional","affiliation":[{"name":"CHU Lille, Unit\u00e9 Fonctionnelle de Toxicologie  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Gaulier","sequence":"additional","affiliation":[{"name":"CHU Lille, Unit\u00e9 Fonctionnelle de Toxicologie  Lille France"},{"name":"University Lille, EA 4483 \u2013 IMPECS \u2013 IMPact de l'Environnement Chimique sur la Sant\u00e9 humaine  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Di Fazio","sequence":"additional","affiliation":[{"name":"Laboratory of Toxicology National Institute of Criminalistics and Criminology  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Humbert","sequence":"additional","affiliation":[{"name":"CHU Lille, Unit\u00e9 Fonctionnelle de Toxicologie  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Samyn","sequence":"additional","affiliation":[{"name":"Laboratory of Toxicology National Institute of Criminalistics and Criminology  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Allorge","sequence":"additional","affiliation":[{"name":"CHU Lille, Unit\u00e9 Fonctionnelle de Toxicologie  Lille France"},{"name":"University Lille, EA 4483 \u2013 IMPECS \u2013 IMPact de l'Environnement Chimique sur la Sant\u00e9 humaine  Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,27]]},"reference":[{"key":"e_1_2_5_2_1","unstructured":"European Commission DGMobility and Transport. Road Safety in the European Union European Commission 2015.http:\/\/ec.europa.eu\/transport\/road_safety\/pdf\/vademecum_2015.pdf[7 July 2017]."},{"key":"e_1_2_5_3_1","unstructured":"HouwingS HagenziekerM MathijssenR et al.DRUID\u2010Deliverable 2.2.3\u2010Part I; Prevalence of Alcohol and Other Psychoactive Substances in General Traffic. General Results SWOV Leidschendam 2011."},{"key":"e_1_2_5_4_1","unstructured":"HelsT BerhoftIM LyckegaardA et al.DRUID\u2010Deliverable 2.3.5. Risk of Injury by Driving with Alcohol and Other Drugs Danish Transport Research Institute Kongens Lyngby 2012."},{"key":"e_1_2_5_5_1","unstructured":"Parliament of Belgium.Wet tot wijziging van de wet betreffende de politie over het wegverkeer geco\u00f6rdineerd op 16 maart 1968 (1) (Loi modifiant la loi relative \u00e0 la police de la circulation routi\u00e8re coordonn\u00e9e le 16 mars 1968) 16 maart (mars) 1999 Belgisch Staatsblad (Moniteur Belge) 30.03.1999."},{"key":"e_1_2_5_6_1","unstructured":"Parliament of France.Loi n\u00b0 2003\u201387 Relative \u00e0 la conduite sous l'influence de substances ou plantes classes comme stup\u00e9fiants 3 f\u00e9vrier2003."},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0379-0738(01)00450-9"},{"key":"e_1_2_5_8_1","unstructured":"CederG.Drugged driving in Sweden \u2013 effects of new legislation concerning zero\u2010tolerance for narcotic drugs. In: H. Laurell ed.Proceedings of the 15thInternational Conference of Alcohol Drugs and Traffic Safety (ICADTS) Stockholm (Sweden) 2000."},{"key":"e_1_2_5_9_1","doi-asserted-by":"crossref","unstructured":"Parliament of Victoria.Road safety (drug driving) act 2003 111\/2003 2003.","DOI":"10.2208\/jscej.2003.749_111"},{"key":"e_1_2_5_10_1","first-page":"32","article-title":"Council Decision 2005\/387\/JHA of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances","year":"2005","journal-title":"Official Journal L 127"},{"key":"e_1_2_5_11_1","unstructured":"EMCDDA.New Psychoactive Substances in Europe \u2013 an update from the EU early warning system 2015 EMCCDAhttp:\/\/www.emcdda.europa.eu\/publications\/2015\/new\u2010psychoactive\u2010substances. Accessed March 25 2015."},{"key":"e_1_2_5_12_1","unstructured":"European Commission.Flash Eurobarometer 401: Young People and Drugs 2014 European Commission 2014 Young People and Drugs Flash Eurobarometer 401.http:\/\/ec.europa.eu\/public_opinion\/flash\/fl_401_en.pdf\/[7 July 2017]."},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-016-1812-x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1556-4029.12550"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bku067"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/15389588.2015.1018990"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1535"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1556-4029.12407"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aap.2013.09.009"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2011.03.015"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/15389588.2015.1036157"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-015-1150-1"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/anatox\/35.8.577"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2008.09.032"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31828e7e6b"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1865"},{"key":"e_1_2_5_27_1","article-title":"Detection of the designer benzodiazepine metizolam, in urine and preliminary data on its metabolism","author":"Kintz P","year":"2016","journal-title":"Drug Test Anal"},{"key":"e_1_2_5_28_1","article-title":"Challenges concerning new psychoactive substance detection in oral fluid","author":"Wille SMR","year":"2017","journal-title":"Toxac."},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.09.002"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2012.184929"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1688"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2056"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3193"},{"key":"e_1_2_5_34_1","first-page":"16","article-title":"Dried saliva spots (DSS), tests immunochimiques de d\u00e9pistage salivaire et produits stup\u00e9fiants","volume":"29","author":"Richeval C","year":"2017","journal-title":"Toxic Analyt Clin."},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.01.024"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1924"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-016-0362-1"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.12.011"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-015-1280-5"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2006.09.001"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00097-9"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11419-016-0309-x"},{"key":"e_1_2_5_43_1","volume-title":"Tryptamines. In: Novel Psychoactive Substances: Classification, Pharmacology and Toxicology","author":"Greene SL","year":"2013"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.2232","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.2232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T06:27:14Z","timestamp":1760423234000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.2232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,27]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/dta.2232"],"URL":"https:\/\/doi.org\/10.1002\/dta.2232","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,27]]}}}